ViroPharma (VPHM) up 4.5% premarket to $9.35, as Oppenheimer upgrades it to Outperform with a...

|By:, SA News Editor

ViroPharma (VPHM) up 4.5% premarket to $9.35, as Oppenheimer upgrades it to Outperform with a $13 target based on a potential revenue surprise for its Cinryze product.